Get started
Author

Yanira Heredia

Observed name: Yanira Ruiz Heredia
OpenAlex ID: A5055020157
How useful is molecular modelling in combination with ion mobility mass spectrometry for ‘small molecule’ ion mobility collision cross-sections?
2015 · Cris Lapthorn, Frank S. Pullen, et al. · The Analyst · 53
Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges
2024 · Noemí Álvarez, Alejandro Martín, et al. · Frontiers in Immunology · 11
Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer
2025 · Iñaki Comino-Méndez, Jesús Velasco-Suelto, et al. · Breast Cancer Research · 10
PDF
Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH
2021 · Ana Jimenez-Ubieto, María Poza, et al. · Blood · 4
Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients
2020 · Ana Isabel Jiminez Ubieto, Yanira Heredia, et al. · Blood · 4
Detection of Emerging Resistant Clones in Philadelphia-Positive Leukemia Patients Exposed to Tyrosine Kinase Inhibitors. Correlation of cDNA and Gdna Approaches
2020 · Ricardo Sanchez, Juan Manuel de la Rosa, et al. · Blood · 1
P702: Application of Next Generation Sequencing (ngs) for Minimal Residual Disease (mrd) and Chimerism Monitoring in Myelodysplastic Syndrome (mds) After Allogenic Stem Cell Transplantation (asct)
2023 · Irene Zamanillo, Santiago Barrio, et al. · HemaSphere
Pb1781: the Application of Cf-dna for Ngs Mrd Studies in Patients With Lma Improves the Sensitivity of the Method With Respect to Ctc.
2023 · Noemí Álvarez Sánchez-Redondo, Alejandro Martin, et al. · HemaSphere
Desarrollo de estrategias basadas en técnicas moleculares y test farmacológicos para la implantación de protocolos de medicina personalizada en el tratamiento del mieloma múltiple
2019 · Yanira Heredia · Dialnet (Universidad de la Rioja)
Mitochondrial activity plays a critical role in multiple myeloma resistance.
2018 · Haematology Neoplasms group, CNIO, Madrid, Spain., Alejandra Ortiz Ruiz, et al. · IBJ Plus
Targeted Genomic Mutation Panel (M3 P) Results from 504 Multiple Myeloma (MM) Patients
2015 · K Martin Kortuem, Esteban Braggio, et al. · Blood
Works count: 11
Citation count: 83
H-index: 4
I10-index: 3
Year
Topic
Type